Differential clinical pharmacology of rolapitant in delayed chemotherapy-induced nausea and vomiting (CINV)

about

Onychomadesis associated with chemotherapy: case report and mini literature review.Rolapitant: A Review in Chemotherapy-Induced Nausea and Vomiting.

P2860

Q41475853-6535B93B-2343-447E-A49A-DCB5D8BEDC49 Q50001512-D523A64C-9C61-4F61-9E3F-086A8B598F22

P2860

Differential clinical pharmacology of rolapitant in delayed chemotherapy-induced nausea and vomiting (CINV)

Item

http://www.wikidata.org/entity/Q37730595

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 24 March 2017

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Differential clinical pharmaco ...... ced nausea and vomiting (CINV)

@en

Differential clinical pharmaco ...... py-induced nausea and vomiting

@nl

type

Item

label

Differential clinical pharmaco ...... ced nausea and vomiting (CINV)

@en

Differential clinical pharmaco ...... py-induced nausea and vomiting

@nl

prefLabel

Differential clinical pharmaco ...... ced nausea and vomiting (CINV)

@en

Differential clinical pharmaco ...... py-induced nausea and vomiting

@nl

P1476

Differential clinical pharmaco ...... ced nausea and vomiting (CINV)

@en

P2093

Noha Rashad

http://www.w3.org/2001/XMLSchema#string

Omar Abdel-Rahman

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial

P2860

Neurokinin-1 inhibitors in the prevention of nausea and vomiting from highly emetogenic chemotherapy: a network meta-analysis

Substance P: a pioneer amongst neuropeptides.

A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy.

A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy.

Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study.

Antiemetics: American Society of Clinical Oncology clinical practice guideline update.

Potential role of the NK1 receptor antagonists in chemotherapy-induced nausea and vomiting.

Rolapitant (SCH 619734): a potent, selective and orally active neurokinin NK1 receptor antagonist with centrally-mediated antiemetic effects in ferrets.

Rolapitant for the treatment of chemotherapy-induced nausea and vomiting: a review of the clinical evidence.

Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting over multiple cycles of moderately or highly emetogenic chemotherapy.

P304

947-954

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/DDDT.S108872

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P50

Omar Abdel-Rahman

Noha Rashad

P577

2017-03-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28392676

http://www.w3.org/2001/XMLSchema#string

P921

P932

5373840

http://www.w3.org/2001/XMLSchema#string

Differential clinical pharmacology of rolapitant in delayed chemotherapy-induced nausea and vomiting (CINV)

about

P2860

P2860

Differential clinical pharmacology of rolapitant in delayed chemotherapy-induced nausea and vomiting (CINV)

description

name

type

label

prefLabel

P1433

P1476

P2093

P275

P2860

P304

P31

P356

P407

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P275

P2860

P304

P31

P356

P407

P478

P50

P577

P698

P921

P932